Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial

Heart Rhythm

Volumn 11, Issue 6, 2014, Pages 925-932

  Steinberg, Benjamin A ^a   Hellkamp, Anne S ^a   Lokhnygina, Yuliya ^a   Halperin, Jonathan L ^b   Breithardt, Günter ^c   Passman, Rod ^d   Hankey, Graeme J ^e   Patel, Manesh R ^a   Becker, Richard C ^f   Singer, Daniel E ^g   Hacke, Werner ^h   Berkowitz, Scott D ⁱ   Nessel, Christopher C ^j   Mahaffey, Kenneth W ^k   Fox, Keith A A ^l   Califf, Robert M ^m   Piccini, Jonathan P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ BAYER CORPORATION   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF EDINBURGH   (United Kingdom)

^m DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Outcomes; Rivaroxaban; Warfarin

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; FLECAINIDE; PROPAFENONE; QUINIDINE; RIVAROXABAN; SOTALOL; WARFARIN; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; PLACEBO;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ATRIAL FIBRILLATION; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MORTALITY; DRUG EFFICACY; DRUG USE; INTERNATIONAL NORMALIZED RATIO; MORBIDITY; OUTCOME ASSESSMENT;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MORPHOLINES; THIOPHENES; TREATMENT OUTCOME;

EID: 84901603918     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.03.006     Document Type: Article

References (15)

1. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
2. A.F. ROCKET Study Investigators. Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347 e341
3. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
4. L.J. Wie, D.Y. Lin, and L. Weissfeld Regression analysis of multivariate incomplete failure time data by modeling marginal distribution J Am Stat Assoc 84 1989 1065 1073
5. A. Guerin, J. Lin, M. Jhaveri, E.Q. Wu, A.P. Yu, M. Cloutier, G. Gauthier, and J.S. Alpert Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy Int J Cardiol 167 2013 564 569
6. N.Z. Kerin, R.D. Blevins, L. Goldman, K. Faitel, and M. Rubenfire The incidence, magnitude, and time course of the amiodarone-warfarin interaction Arch Intern Med 148 1988 1779 1781
7. Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell, P. Glasziou, C. Bankhead, and Y. Xu Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2008 84 91
8. J.S. Steinberg, A. Sadaniantz, and J. Kron et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Circulation 109 2004 1973 1980
9. C. Lafuente-Lafuente, M.A. Longas-Tejero, J.F. Bergmann, and J. Belmin Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation Cochrane Database Syst Rev 5 2012 CD005049
10. E.G. Daoud, T.V. Glotzer, D.G. Wyse, M.D. Ezekowitz, C. Hilker, J. Koehler, and P.D. Ziegler TRENDS Investigators. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS Heart Rhythm Sep 8 2011 1416 1423
11. M.J. Gnoth, U. Buetehorn, U. Muenster, T. Schwarz, and S. Sandmann In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban J Pharmacol Exp Ther 338 2011 372 380
12. J.D. Wessler, L.T. Grip, J. Mendell, and R.P. Giugliano The P-glycoprotein transport system and cardiovascular drugs J Am Coll Cardiol 61 2013 2495 2502
13. J.P. Piccini, S.R. Stevens, and Y. Lokhnygina et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
14. G.C. Flaker, S. Hohnloser, D. Wojdyla, E. Hylek, D. Garcia, R. Sullivan, R. Lopes, S.M. Al-Khatib, and C. Granger Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE Trial J Am Coll Cardiol 61 2013 E317-E317
15. A. Blandino, E. Toso, M. Scaglione, M. Anselmino, F. Ferraris, D. Sardi, A. Battaglia, and F. Gaita Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation J Cardiovasc Electrophysiol 24 2013 731 738